Bristol Myers Squibb (BMY) Stock Analysis

Catalysts

• Camzyos is the center of gravity for BMY's near-term growth narrative — an FDA decision on adolescent HCM could be a meaningful catalyst in the coming months.
• Competitive threats in HCM are emerging — Edgewise and likely others are drawing investor comparisons, which could pressure Camzyos's premium positioning over time.
• The oncology pipeline remains active but early-stage — the pumitamig data is encouraging but interim Phase 2; investors should watch for registration-enabling data.

Risks

• Event-driven repricing risk if expectations diverge from incoming evidence.